



Release certificate

| | | | |
|-----------------------|--|---|------------------|
| Product | Cannabis flos, variety Bediol (hemp flowers) THC/CBD-intermediate type to be prescribed to patients as a medicinal product | | |
| Strength | tetrahydrocannabinol: $\geq 1.0\%$ cannabidiol: $\geq 1.0\%$ total tetrahydrocannabinol / total cannabidiol ratio: 0.2 – 5.0 | | |
| Dosage form | flowers, granulated | | |
| Package size and type | 5 grams in container, 400 grams in bags | | |
| Testing method | European Pharmacopoeia (Ph. Eur.) 07/2024:3028 | | |
| Batch | 25I22FB25J15 | | |
| Order numbers | containers | 387429 to 387437 | |
| | bags | 387428 | |
| Expiry date | 31 Aug 2026 | | |
| Grower/drier | Bedrocan Nederland B.V. P.O. Box 2009 NL- 9640 CA Veendam | harvest date: | 22 Sep 2025 |
| Gamma irradiation | Synergy Health Ede B.V. Soevereinstraat 2 NL-4879 NN Etten-Leur | date: | 15 Oct 2025 |
| | Fagron Nederland B.V. Venkelbaan 101 NL-2908 KE Capelle a/d IJssel | dose: | $\geq 10,0$ kGy |
| Packager | | date: | 05 – 13 Nov 2025 |
| Laboratory | Laboratorium Ofichem B.V. Heembadweg 5 NL-9561 CZ Ter Apel | 1. General analysis Analysis number: | 54752 |
| | | Report date: | 21 Oct 2025 |
| | | 2. Microbiology of end product in container | |
| | | Analysis number: | 55115 |
| | | Report date: | 18 Nov 2025 |



| Results of analysis | | | |
|---|-------------------------------------|---|-----------|
| | Method | Specification | Result |
| Appearance | Visual | Dried, fragmented, fully developed female inflorescence of Cannabis sativa L. | Complies |
| | | Stalks are no longer than 2.0 cm and only 20% of the stalks are between 1.5 and 2.0 cm. | |
| Identification | | | |
| Macroscopic botanical characters | Monograph | Conform Identification A. | Complies |
| Microscopic botanical characters | Monograph | Conform Identification B. | Complies |
| High-performance thin-layer chromatography | Monograph | Comparable with reference and test solutions THC/CBD-intermediate type. Conform Identification C. | Complies |
| Loss on drying | Monograph | ≤ 12.0% | 7.8 % |
| | | Maximum 2% | 1 % |
| Foreign material | Monograph | It does not contain any seeds or other foreign elements and the whole herbal drug does not contain any leaves more than 1.0 cm in length. | Complies |
| Aflatoxins | | | |
| Aflatoxin B ₁ | Ph. Eur. | ≤ 2 µg/kg | < 2 µg/kg |
| Sum of aflatoxins B ₁ , B ₂ , G ₁ and G ₂ | (current ed.) 2.8.18 | ≤ 4 µg/kg | < 4 µg/kg |
| Pesticides | Ph. Eur. (current ed.) 2.8.13 | ≤ Limits Ph. Eur. 2.8.13* | Complies |
| Heavy metals | | | |
| Arsenic | Monograph | ≤ 0.2 ppm | < 0.1 ppm |
| Cadmium | | ≤ 0.3 ppm | < 0.2 ppm |
| Lead | | ≤ 0.5 ppm | < 0.3 ppm |
| Mercury | | ≤ 0.1 ppm | < 0.1 ppm |



| Results of analysis | | | |
|--|------------------------|---------------------------|----------------------------|
| | Method | Specification | Result |
| Assay (HPLC) | | | |
| Tetrahydrocannabinol (THC, total equivalent) | Monograph | ≥ 1.0% | 7.0 % |
| Cannabidiol (CBD, total equivalent) | | ≥ 1.0% | 9.6 % |
| total tetrahydrocannabinol / total cannabidiol ratio | Calculation | 0.2 – 5.0 | 0.7 |
| Related substances (HPLC) | | | |
| Cannabinol (CBN, total equivalent) | Monograph | ≤ 1.0% | < 0.1 % |
| Microbial contamination | | | |
| Total aerobic microbial count (TAMC) | | ≤10 ² cfu/gram | < 10 ² cfu/gram |
| Total combined yeasts/moulds count (TYMC) | Ph. Eur. (current ed.) | ≤10 ¹ cfu/gram | < 10 ¹ cfu/gram |
| S. aureus, P. aeruginosa, bile-tolerant gram-negative bacteria | 2.6.12, 2.6.13 | Absent (1 gram) | Complies |

**The following pesticides are not analysed: dithiocarbamates (expressed as CS₂), methoxychlor, paraoxon-methyl and tetradifon. The limit of detection is increased for fenpropathrin to 0.1 mg/kg and azinphos-ethyl to 1 mg/kg.*

I hereby certify that the above information is authentic and accurate. This batch of product has been cultivated, manufactured, gamma irradiated, packaged and tested in full compliance with the GACP and GMP requirements and with the specifications as stated in this document.

The Hague, the Netherlands, 28 November 2025

M. Mennens / S. Vos- de Schipper
QA, Office of Medicinal Cannabis